Williamsport, PA (1888PressRelease)
August 03, 2008 - IMGENEX Corporation, a San Diego based company, has obtained exclusive world-wide rights to US Patent no. 5,830,451 from Brigham & Women's Hospital, Boston, to develop and market the EBI3-p35 fusion protein also known as Interleukin 35 (IL-35), for research purposes. IL-35 is a novel IL-12 family cytokine produced by regulatory T cells (Treg) shown to suppress immune response through expansion of Treg cells.
Dr. Sujay Singh, President & CEO of IMGENEX , said that the license will allow IMGENEX to expand their presence in the regulatory T cell reagent market and facilitate new product development. " IL-35 has been strongly implicated as a key player in regulating inflammatory processes. Securing this license will allow IMGENEX to expand its presence in a key market and sustain its role as an innovator in the life science industry."
For more information visit: http://www.imgenex.com
Address:-
Imgen Corporation
11175 Flintkote Avenue
SAN DIEGO, CA 92121-1318 , US
(858) 642-0978
Fax: 999 999 9999
###
